393 related articles for article (PubMed ID: 32856962)
1. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
Sun M; Cole AP; Hanna N; Mucci LA; Berry DL; Basaria S; Ahern DK; Kibel AS; Choueiri TK; Trinh QD
J Urol; 2018 Jun; 199(6):1417-1425. PubMed ID: 29410294
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
Nead KT; Sinha S; Nguyen PL
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):259-264. PubMed ID: 28349979
[TBL] [Abstract][Full Text] [Related]
4. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
[TBL] [Abstract][Full Text] [Related]
5. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
[TBL] [Abstract][Full Text] [Related]
6. Association Between Androgen Deprivation Therapy and Risk of Dementia.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH
JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437
[TBL] [Abstract][Full Text] [Related]
7. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
8. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
9. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
10. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
11. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
[TBL] [Abstract][Full Text] [Related]
12. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
13. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract][Full Text] [Related]
15. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
Niraula S; Le LW; Tannock IF
J Clin Oncol; 2013 Jun; 31(16):2029-36. PubMed ID: 23630216
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for prostate cancer and risk of dementia.
Robinson D; Garmo H; Van Hemelrijck M; Damber JE; Bratt O; Holmberg L; Wahlund LO; Stattin P; Adolfsson J
BJU Int; 2019 Jul; 124(1):87-92. PubMed ID: 30637900
[TBL] [Abstract][Full Text] [Related]
17. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.
Cui H; Wang Y; Li F; He G; Jiang Z; Gang X; Wang G
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):15-23. PubMed ID: 32814845
[TBL] [Abstract][Full Text] [Related]
18. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
Schmid M; Hanske J; Ravi P; Krishna N; Reznor G; Meyer CP; Fisch M; Noldus J; Nguyen PL; Trinh QD
Int J Urol; 2016 Apr; 23(4):305-11. PubMed ID: 26763083
[TBL] [Abstract][Full Text] [Related]
19. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
Baik SH; Kury FSP; McDonald CJ
J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
[TBL] [Abstract][Full Text] [Related]
20. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
Kratiras Z; Konstantinidis C; Skriapas K
Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]